section name header

Evidence summaries

Recombinant Human Interleukin 10 for Induction of Remission in Crohn's Disease

Recombinant human interleukin 10 might possibly increase the number of remissions, complete or clinical, compared to placebo in the treatment of refractory Crohn's disease, but the evidence is insufficient for conclusions. Level of evidence: "D"

The quality of evidence is downgraded by imprecise result, inconsistency (heterogeneity of results across trials) and potential reporting bias (only few small trials reported).

A Cochrane review 1 [Abstract] included 3 studies with a total of 470 subjects comparing human recombinant interleukin 10 to placebo for induction of remission in Crohn's disease.

There was no statistically significant difference in the number of complete remissions in patients that received interleukin 10 compared to placebo (79 events, 3 trials; RR 1.43; 95% CI 0.62 to 3.29). Serious adverse (99 events, 1 trial) events were more frequent in the IL-10 group compared to placebo, but the difference was not statistically significant (RR 1.13; 95 % CI 0.73 to 1.74)

References

  • Buruiana FE, Solà I, Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010;(11):CD005109. [PubMed]

Primary/Secondary Keywords